3 Phase III trials suggest cognitive side effects from radiation therapy for brain metastases may be reversible, with 75% of patients regaining some cognitive function.

A pooled analysis of three Phase III clinical trials presented at the ASTRO Annual Meeting indicates that cognitive side effects from radiation therapy in patients with brain metastases may be fully reversible. Recovery rates were 38% at six months and 42% at one year post-cognitive decline, with improved outcomes seen in those treated with conformal radiation techniques compared to standard whole-brain therapy. Overall, about 75% of patients regained some cognitive function.

September 29, 2024
4 Articles